J. Rodon

Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.

Yuan Qi, G. Mills, Y. Qi, 2019, JCO precision oncology.

SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA 9)

F. Meric-Bernstam, A. Naing, K. Kurnit, 2023, Gynecologic Oncology.